Drug intelligence / Profile preview

TRRP@DOX

Development stage: Preclinical
Lead developer: Chinese PLA Medical School
Modality: Peptides, Small Molecules
Administration: Intra-arterial

Overview

TRRP@DOX is a preclinical, doxorubicin-loaded targeted redox-responsive peptide drug-delivery system designed for transcatheter arterial chemoembolization of hepatocellular carcinoma. The peptide carrier binds transferrin receptor on tumor-cell surfaces and releases doxorubicin preferentially under the elevated glutathione conditions of tumor cells; doxorubicin then mediates cytotoxicity principally through DNA intercalation and topoisomerase II inhibition. In an orthotopic rat hepatocellular carcinoma model, TRRP@DOX dispersed in lipiodol improved therapeutic outcomes versus a conventional doxorubicin plus lipiodol emulsion. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11519146/))

Other names: TRRP@DOX

Targets

DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on TRRP@DOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRRP@DOX.

Explore the full profile